in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Lonza reports fall in profits, sales
2:56 AM MST | January 23, 2014 | Deepti Ramesh
Lonza recorded a 44.2% fall in profits for 2013 compared with 2012, to 87 million Swiss francs ($95.7 million). Sales for 2013 decreased by 4.2%, to SF3.58 billion, due to lower sales in the water treatment business; product portfolio optimization measures; unfavorable exchange rate translation effects; weaker pharma and biotech sales in the first half of the year; and the previously announced phase down of the company’s microbial biologics plant at Hopkinton, MA, Lonza says. Core Ebit for 2013 increased by 11.2%, however, to SF436 million. In line with the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee